Beam Therapeutics Inc (BEAM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has a cash flow conversion efficiency ratio of -0.062x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-66.10 Million) by net assets ($1.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Beam Therapeutics Inc for the company's overall valuation and market capitalisation.
Beam Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beam Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beam Therapeutics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Beam Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
-0.045x |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
-0.005x |
|
Central Puerto S.A.
BA:CEPU
|
0.014x |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
0.002x |
|
Bure Equity AB
ST:BURE
|
0.016x |
|
Maple Leaf Foods Inc.
TO:MFI
|
0.044x |
|
Proximus NV
BR:PROX
|
0.076x |
|
SCHOTT Pharma AG & Co. KGaA
XETRA:1SXP
|
0.096x |
Annual Cash Flow Conversion Efficiency for Beam Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Beam Therapeutics Inc from 2017 to 2025. View BEAM live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.24 Billion | $-345.10 Million | -0.279x | +41.13% |
| 2024-12-31 | $733.54 Million | $-347.25 Million | -0.473x | -211.37% |
| 2023-12-31 | $981.33 Million | $-149.19 Million | -0.152x | -595.02% |
| 2022-12-31 | $733.47 Million | $22.53 Million | 0.031x | +138.32% |
| 2021-12-31 | $826.74 Million | $-66.27 Million | -0.080x | +79.44% |
| 2020-12-31 | $245.56 Million | $-95.74 Million | -0.390x | +45.34% |
| 2019-12-31 | $100.94 Million | $-72.00 Million | -0.713x | -370.99% |
| 2018-12-31 | $134.03 Million | $-20.30 Million | -0.151x | -123.40% |
| 2017-12-31 | $-4.18 Million | $-2.71 Million | 0.647x | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more